Page 260 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 10
Table 1. Baseline characteristics of patients who underwent three or four DPD phenotyping assays and from the main study cohort
Characteristic
Sex
Male Female
Age
Median [IQR]
Ethnic origin
Caucasian African descent
Asian Other
Tumour type
Non-metastatic CRC Metastatic CRC BC
GC Other
Type of treatment regimen
CAP mono CAP + RT CAPOX CAP other 5-FU mono 5-FU + RT FOLFOX 5-FU other
BSA
Median [IQR]
WHO performance status
0 1 2 NS
Number of treatment cycles
Median [IQR]
DPYD status
Wild-type DPYD variant allele carrier
c.1236G>A heterozygous c.2846A>T heterozygous DPYD*2A heterozygous c.1679T>G heterozygous
Phenotyping assays (N=92)
56 (61%) 36 (39%)
60 [53-67]
87 (95%) 1 (1%)
2 (2%)
2 (2%)
38 (41%) 23 (25%) 7 (8%)
7 (8%) 17 (18%)
12 (13%) 23 (25%) 37 (40%) 5 (5%)
-
6 (7%) 4 (4%) 5 (5%)
2.0 [1.79-2.10] (N=91) 49 (53%)
41 (45%) 1 (1%)
1 (1%)
3 [1-6]
82 (89%) 10 (10.9%)
6 (6.5%) 3 (3.3%) 1 (1.1%) -
Main study cohort (N=1,103)
593 (54%) 510 (46%)
64 [56-71]
1048 (95%) 19 (2%)
24 (2%)
12 (1%)
472 (43%) 232 (21%) 141 (13%) 63 (6%) 195 (18%)
205 (19%) 264 (24%) 374 (34%) 72 (7%)
2 (0%) 63 (6%) 43 (4%) 80 (7%)
1.92 [1.77-2.10] (N=1075) 554 (50%)
448 (40%) 42 (4%) 59 (5%)
3 [1-8]
1018 (92%) 85 (7.7%)
51 (4.6%) 17 (1.5%) 16 (1.5%) 1 (0.1%)
P-valuea
0.189
0.011 0.786
ND
0.854
0.207 0.151
0.987 0.281
a All p-values represent a comparison of 92 patients who underwent three or four DPD phenotyping
258